MwanzoCRSP • NASDAQ
add
Crispr Therapeutics AG
Bei iliyotangulia
$Â 41.29
Bei za siku
$Â 38.51 - $Â 40.37
Bei za mwaka
$Â 38.20 - $Â 91.10
Thamani ya kampuni katika soko
3.39B USD
Wastani wa hisa zilizouzwa
1.79M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu 602.00 | — |
Matumizi ya uendeshaji wa biashara | 17.42M | -4.77% |
Mapato halisi | -85.94M | 23.37% |
Kiwango cha faida halisi | elfu -14.28 | — |
Mapato kwa kila hisa | -1.01 | 28.37% |
EBITDA | -105.39M | 17.33% |
Asilimia ya kodi ya mapato | -1.03% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 1.94B | 11.26% |
Jumla ya mali | 2.26B | 8.11% |
Jumla ya dhima | 316.47M | -11.86% |
Jumla ya hisa | 1.94B | — |
hisa zilizosalia | 85.35M | — |
Uwiano wa bei na thamani | 1.82 | — |
Faida inayotokana na mali | -11.98% | — |
Faida inayotokana mtaji | -12.57% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -85.94M | 23.37% |
Pesa kutokana na shughuli | -106.91M | -168.25% |
Pesa kutokana na uwekezaji | -161.60M | -233.17% |
Pesa kutokana na ufadhili | 9.64M | 519.54% |
Mabadiliko halisi ya pesa taslimu | -258.80M | -411.81% |
Mtiririko huru wa pesa | -80.67M | -495.63% |
Kuhusu
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Ilianzishwa
2013
Makao Makuu
Tovuti
Wafanyakazi
407
